AstraZeneca will soon start a phase 3 trial of a subcutaneous version of its anti-CD19 T-cell engager.
ApexOnco Front Page
Recent articles
A son of glembatumumab vedotin has just started its phase 1 study.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
And the company says it won’t need to carry out another trial.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
And that could affect the drug's third-line accelerated approval.
A fresh licensing deal tidies up years of work between the two companies.
